跳至主要内容
临床试验/DRKS00023016
DRKS00023016已完成不适用

Differentiation of cerebral metastases of lung cancer using apparent diffusion coefficient (ADC) maps - LUMETADC

niversitätsmedizin Göttingen0 个研究点目标入组 600 人开始时间: 2020年9月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • Patients with pathologically confirmed SCLC or NSCLC and an MRI of the brain, regardless of the MRI manufacturer or the field strength. It must only contain (i) a T1-weighted sequence with contrast agent (CA), (ii) a T2-weighted sequence for detecting zystic parts and (iii) a DWI Sequence with ADC Mapping.

排除标准

  • Patients are excluded, if
  • (1) brain metastasis are not detected by MRI, (2) the size of the found solid tumour parts were not large enough (<0.25 cm²) for measurements or (3) more than one tumour origin was known at time of MRI.
  • Brain metastases with large intratumoral haemorrhage (>50% of the solid tumour part) were excluded.

研究者

发起方
niversitätsmedizin Göttingen

相似试验